Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond – FierceBiotech

by

  1. Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond FierceBiotech
  2. Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure STAT
  3. Mirum Pharmaceuticals buys Travere Therapeutics portfolio of bile acid drugs for up to $445M – San Francisco Business Times The Business Journals
  4. Sanofi goes back to Scribe Evaluate Pharma
  5. East Bay’s Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease – San Francisco Business Times The Business Journals
  6. View Full Coverage on Google News

Read original article here

Leave a Comment